FRANCE – Corteria Pharmaceuticals (Corteria) has tapped Dr. Mark Pruzanski as the new Chairman of the biopharmaceutical company’s Board of Directors.
In a press release, Philip Janiak, Founder and Chief Executive Officer of Corteria Pharmaceuticals, said: “We are thrilled to welcome Dr. Mark Pruzanski as the Chairman of the Board of Directors.”
As the incoming Chairman of its Board of Directors, Dr. Mark Pruzanski replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the board.
Corteria Pharmaceuticals is a privately held biopharmaceutical company developing first-in-class drugs, with an initial focus on the treatment of heart failure.
Founded in 2021, the French biopharmaceutical company specializes in the development of transformative therapies for heart failure and obesity.
The company’s latest executive appointment comes as the prevalence of heart failure keeps increasing, with more than 60 million patients worldwide, despite improvements in the management of the chronic condition.
“His strategic vision, outstanding leadership, and passion for innovation make Mark a valuable addition to Corteria as we continue our mission to advance innovative therapeutic solutions for heart failure and obesity,” stated Philip Janiak.
As the company’s board chairman, Dr. Mark Pruzanski brings extensive expertise in drug development with a solid track record in the biotechnology industry.
In varying roles, Dr. Mark Pruzanski has more than 30 years of experience as a life sciences executive, entrepreneur, and investor.
Before his current role, he served as the Chairman and Chief Executive Officer of Versanis Bio, a private clinical-stage biopharmaceutical company, which was acquired by Eli Lilly in July 2023.
He also founded Intercept Pharmaceuticals and was the company’s CEO until 2021, having led its evolution from a drug discovery stage to a global development and commercial organization with a focus on addressing chronic liver diseases.
Besides establishing Intercept Pharmaceuticals, Dr. Pruzanski currently serves as a board member of a wide range of private and public biotechnology companies.
These biotechnology companies include the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security.
It is worth highlighting that Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, an M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy, and Washington, D.C.
In addition to the higher education experience, the renowned entrepreneur earned a bachelor’s degree in Political Science from McGill University in Montreal, Canada.
In his address, Dr. Mark Pruzanski, Chairman of the Corteria Pharmaceuticals Board of Directors, said: “This is an exciting time in the company’s evolution as it brings its impressive first-in-class assets into the clinic, on the heels of its recent Series A financing led by top tier biotech investors.”
Dr. Mark Pruzanski expressed his readiness to work with Philip Janiak, Founder and Chief Executive Officer of Corteria Pharmaceuticals, and the other members of the board to help ensure the biopharmaceutical company’s future success.